Forge Biologics to develop, manufacture GentiBio therapies

By The Science Advisory Board staff writers

July 15, 2021 -- GentiBio and Forge Biologics have formed a strategic development and manufacturing partnership to advance GentiBio's immune tolerance platform.

Under the agreement, Forge, a cell and gene therapy-focused contract development and manufacturing organization (CDMO), will provide adeno-associated viral (AAV) vector process and analytical development, scale-up engineering, and good manufacturing practice (GMP) manufacturing services for GentiBio's therapeutic candidates based on the company's engineered T regulatory cells (Tregs).

GentiBio's autologous and allogeneic EngTregs platform restores immune tolerance to overcome major limitations in existing Tregs therapeutics.

GentiBio's process development will utilize Forge's Blaze Vector production platform as well as HEK 293 suspension ignition cells. All development and GMP activities will take place at Forge's 175,000-sq-ft facility in Columbus, OH.

Financial details of the partnership were not disclosed.

Forge Biologics, Case Western train gene therapy workers
Contract development and manufacturing organization Forge Biologics and Case Western Reserve University in Cleveland announced that they will collaborate...
Forge secures $120M to increase AAV manufacturing capacity
Contract development and manufacturing organization Forge Biologics has closed $120 million in financing to accelerate the expansion of its adeno-associated...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter